CAR-T cell update: Therapy improves outcomes for patients with B-cell lymphoma

(University of Chicago Medical Center) An international phase-2 trial of a CAR-T cell therapy--to be published on-line Dec. 1 in the New England Journal of Medicine (and presented at the ASH annual meeting in San Diego)--found that 52 percent of patients responded favorably to the therapy; 40 percent had a complete response and 12 percent had a partial response. One year later, 65 percent percent of those patients were relapse-free, including 79 percent of complete responders. The median progression-free survival 'has not been reached.'
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news